A carregar...
Overcoming Ibrutinib Resistance in Chronic Lymphocytic Leukemia
Ibrutinib is the first Bruton’s tyrosine kinase (BTK) inhibitor, which showed significant clinical activity in chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL) patients regardless of cytogenetic risk factors. Recent results of phase III clinical trials in treatment-naïve CLL p...
Na minha lista:
| Publicado no: | Cancers (Basel) |
|---|---|
| Main Authors: | , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
MDPI
2019
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6966427/ https://ncbi.nlm.nih.gov/pubmed/31766355 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers11121834 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|